Physician profile
Cesar C Ochoa
NPI 1255637781
$1,315.44
in general payments reported to CMS, 2019-2025
9 companies · $837 in 2025
The $837 reported for 2025 was more than what 95% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.25 · 2020: $11.60 · 2022: $64.30 · 2024: $304 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $750 · Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $750.00 |
| Food and Beverage | $391.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $750.00 | 2025 | |
| Lilly USA, LLC | $141.42 | 2024 | Mounjaro |
| Abbvie INC. | $123.23 | 2024-2025 | |
| Novo Nordisk INC | $91.33 | 2019-2025 | Wegovy |
| Adaptive Biotechnologies Corporation | $64.30 | 2022 | |
| Corcept Therapeutics | $59.35 | 2024 | Korlym |
| Amarin Pharma, INC. | $59.25 | 2019 | |
| Xeris Pharmaceuticals, INC. | $14.96 | 2025 | Gvoke Hypopen |
| Masimo Corporation | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Ochoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.